Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (IGC) is at the forefront of developing innovative phytocannabinoid-based therapies aimed at treating a wide range of therapeutic indications. The company is involved in cutting-edge research to develop treatments for conditions such as neuropathic and cancer pain, epilepsy, and chronic neurological and oncological diagnoses, which can be life-altering or life-threatening. The mission of IGC Pharma is to alleviate pain, PTSD, seizures, cachexia, and other severe conditions through advanced cannabinoid-based formulations.
One of the primary focuses of IGC Pharma is to combat Alzheimer's disease. The company has developed two investigational drug assets, IGC-AD1 and TGR-63, that have shown potential in reducing key hallmarks of Alzheimer's, such as plaques and tangles, in cell line studies. IGC-AD1, a low-dose tetrahydrocannabinol-based formulation, is currently undergoing a Phase 2 clinical trial involving 146 participants to evaluate its efficacy in treating agitation in dementia due to Alzheimer's.
Beyond Alzheimer's treatment, IGC Pharma also addresses women's health through its wellness brand Holief, which provides relief for premenstrual syndrome and menstrual cramps. This diversified approach highlights the company’s commitment to improving quality of life across various patient demographics.
IGC Pharma's innovative research and development are complemented by strategic partnerships and a robust product portfolio, which collectively enhance its market presence and potential for growth.
IGC Pharma, Inc. (NYSE American:IGC) has announced its participation in the Planet MicroCap Showcase: VEGAS 2023, scheduled for April 26, 2023, at 4:30 PM PDT. CEO Ram Mukunda and CFO Claudia Grimaldi will present and engage in a Q&A session following the presentation.
Investors can access the live presentation via webcast here. Registration for 1x1 investor meetings at the event is available here. The showcase aims to enhance awareness about MicroCap investments.
IGC Pharma focuses on cannabinoid-based formulations for various medical conditions, including Alzheimer’s disease and PMS. The company is currently conducting a Phase 2 clinical trial for its drug IGC-AD1 targeting agitation in Alzheimer’s patients.
India Globalization Capital, Inc. (IGC) reported impressive third fiscal quarter 2023 results, with net revenue soaring 133% to $332,000 year-over-year, driven by its life science segment. The company is advancing its Phase 2 clinical trial for IGC-AD1, targeting agitation in dementia due to Alzheimer’s, expanding sites from four to up to 12 to enhance enrollment. The trial aims to involve 146 patients and establish efficacy over six weeks. R&D expenses rose to $806,000 due to increased trial activities, while SG&A expenses decreased to $1.5 million. Despite a net loss of $2.2 million, IGC remains optimistic about expanding its market presence and future FDA approval.
India Globalization Capital (NYSE American: IGC) announces an upcoming investor webinar featuring CEO Ram Mukunda and PFO Claudia Grimaldi on February 10, 2023, at 12:30 p.m. ET. They will discuss the Company’s Phase 2 trial for IGC-AD1, aimed at alleviating agitation in Alzheimer's patients. The trial involves 146 participants and is categorized as Phase 2B for safety and efficacy. IGC is focused on developing cannabinoid-based formulations for various conditions, including Alzheimer’s disease. The Company also markets wellness brands Holief and Sunday Seltzer.
India Globalization Capital (IGC) announced a no objection letter from Health Canada for its Phase 2 trial of IGC-AD1, targeting agitation in Alzheimer's disease. This approval allows the company to proceed with trials at multiple sites, including Canada and the U.S. CEO Ram Mukunda emphasized the importance of this milestone for patient enrollment and FDA approval. The formulation utilizes low doses of THC and has shown promise in early trials. Approximately 15 million people in North America and Europe are affected by Alzheimer's, highlighting the potential market impact.
India Globalization Capital, Inc. (IGC) has filed a life sciences presentation with the SEC on Form 8K, detailing its initiatives, particularly focusing on low-dose THC drug formulations and cannabinoid-based consumer products.
IGC's leading drug candidate, IGC-AD1, is in Phase 2 trials, targeting agitation in Alzheimer’s dementia. The company also offers CBD products for various health needs. Despite these advancements, the press release includes forward-looking statements subject to risks, such as regulatory challenges and market conditions that could impact product commercialization.
India Globalization Capital, Inc. (NYSE: IGC) has expressed strong support for the Medical Marijuana and Cannabidiol Research Expansion Act, signed into law by President Biden on December 2, 2022. This Act aims to streamline research on marijuana and enhance product availability for medical applications. CEO Ram Mukunda noted that this development is crucial for advancing cannabis research. The company's IGC-AD1 is currently undergoing a Phase 2 clinical trial for Alzheimer’s-related agitation, following promising Phase 1 results showing potential benefits in managing Aβ plaques.
FAQ
What is the current stock price of IGC Pharma (IGC)?
What is the market cap of IGC Pharma (IGC)?
What is the main focus of IGC Pharma, Inc.?
What are IGC Pharma's key investigational drug assets for Alzheimer's?
What is the status of IGC-AD1?
Does IGC Pharma have products targeting women's health?
What conditions does IGC Pharma aim to treat with its therapies?
How does IGC Pharma contribute to Alzheimer's research?
What is the mission of IGC Pharma?
What is the significance of IGC's research on neuropathic and cancer pain?
Does IGC Pharma have any products in the wellness market?
What makes IGC Pharma unique in the biotech industry?
